Terms ending in 2028
Every in-force patent on AstraZeneca AB's record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,163,926 | Process for the Synthesis of Piperidinyl Sulphonate Esters In force · High confidence | Genzyme Corporation | In force | High confidence | |
| US 7,838,675 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,371,292 | Use of Ciclesonide for the Treatment of Respiratory Diseases In force · High confidence | Covis Pharma GmbH | In force | High confidence | |
| US 7,737,149 | N-[5-[2-(3,5-Dimethoxyphenyl)ETHYL]-2H-PYRAZOL-3-YL]-4-(3,5-Dimethylpiperazin-1-YL)BENZAMIDE and Salts Thereof In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,067,413 | 9-Substituted-8-OXO-ADENINE Compounds as Toll-Like Receptor (TLR7 ) Modulators In force · High confidence | Sumitomo Pharma Co., Ltd. | In force | High confidence | |
| US 8,221,786 | Pharmaceutical Formulations Containing an SGLT2 Inhibitor In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,361,972 | Pharmaceutical Formulations Containing an SGLT2 Inhibitor In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,716,251 | Pharmaceutical Formulations Containing An SGLT2 Inhibitor In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 8,129,391 | N-[5-[2-(3,5-Dimethoxyphenyl)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-Dimethylpiperazin-1-YL)BENZAMIDE and Salts Thereof In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 7,618,993 | Compounds In force · High confidence | Alzecure Pharma AB | In force | High confidence | |
| 19 more term ends in 2028 · Pro | |||||
10 of 29 patents shown. Soonest term end first, then patent number.
Pro members see all 29, including 12 expiring within the 18 months from Nov 16, 2026.
19 of these are in force and held by AstraZeneca AB.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.